Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 8:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 821 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Genotype Clear all
Completed Phase 2 Interventional

Erlotinib in Treating Patients With Metastatic and/or Recurrent Head and Neck Cancer

NCT00281866
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
erlotinib hydrochloride
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 12, 2016 · Synced Oct 17, 2026, 8:21 AM EDT
Completed Not applicable Interventional

Effect of Aromatase Inhibitors on Bones and Genes

NCT00603967
View directory record Official record
Conditions
Breast Cancer, Postmenopausal
Interventions
Dual x-ray absorptiometry (DXA), Blood draw, Questionnaire
Procedure · Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
40 Years and older · Female only
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 24, 2013 · Synced Oct 17, 2026, 8:21 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

EEG & Behavioral Predictors of Changes in Smoking Trajectories in Young Light Smokers

NCT02129387
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Not listed
Lead sponsor
Southern Illinois University Carbondale
Other
Eligibility
18 Years to 25 Years
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2021
U.S. locations
1
States / cities
Carbondale, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Oct 17, 2026, 8:21 AM EDT
Completed Not applicable Interventional

Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis

NCT01878513
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Psychotic Disorder Not Otherwise Specified, Severe Bipolar Disorder With Psychotic Features
Interventions
risperidone
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 60 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Oct 17, 2026, 8:21 AM EDT
Completed Phase 2 Interventional

VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C

NCT01581138
View directory record Official record
Conditions
Chronic Hepatitis C Virus
Interventions
VX-222, telaprevir, ribavirin
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 70 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
18
States / cities
Birmingham, Alabama • Anaheim, California • Riverside, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2014 · Synced Oct 17, 2026, 8:21 AM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 Cirrhotics

NCT02304159
View directory record Official record
Conditions
Hepatitis C, Cirrhosis
Interventions
daclatasvir, Sofosbuvir, Sovaldi, Ribavirin
Drug
Lead sponsor
Tarek I. Hassanein, M.D., FACP, FAG, AGAF
Other
Eligibility
18 Years to 75 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Coronado, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Oct 17, 2026, 8:21 AM EDT
Completed No phase listed Observational

Preemptive Genotyping and Pain Management

NCT01813695
View directory record Official record
Conditions
Pain
Interventions
Preemptive genotyping in medical record, Genotyping not included in electronic medical record
Procedure
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 21 Years
Enrollment
576 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 22, 2024 · Synced Oct 17, 2026, 8:21 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.

NCT02032888
View directory record Official record
Conditions
Hepatitis C
Interventions
Daclatasvir, Sofosbuvir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
37
States / cities
Birmingham, Alabama • Beverly Hills, California • Long Beach, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2015 · Synced Oct 17, 2026, 8:21 AM EDT
Completed Phase 2 Interventional Results available

Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer

NCT00940316
View directory record Official record
Conditions
Colorectal Cancer
Interventions
panitumumab, erlotinib hydrochloride, irinotecan hydrochloride
Biological · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
10
States / cities
Arlington Heights, Illinois • Chicago, Illinois • Joliet, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Oct 17, 2026, 8:21 AM EDT
Completed Phase 2 Interventional Results available

Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care

NCT01359644
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
PSI-7977, Daclatasvir, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
17
States / cities
Coronado, California • San Diego, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2015 · Synced Oct 17, 2026, 8:21 AM EDT
Completed Phase 3 Interventional

A Study of Genetic and Environmental Factors and Their Effect on Response to Treatment With Lucentis (Ranibizumab) for Wet AMD

NCT00469352
View directory record Official record
Conditions
Macular Degeneration
Interventions
Ranibizumab
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
50 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 22, 2011 · Synced Oct 17, 2026, 8:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Using Pharmacogenetics to Identify Patients With Polypharmacy at Risk of Medication Adverse Effects

NCT03748355
View directory record Official record
Conditions
Psychiatric Disorder
Interventions
Pharmacogentic Analysis
Genetic
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Oct 17, 2026, 8:21 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study

NCT00500123
View directory record Official record
Conditions
Alpha-1 Antitrypsin Deficiency
Interventions
Alpha-1 Antitrypsin Genotype
Procedure
Lead sponsor
University of Florida
Other
Eligibility
Not listed
Enrollment
50,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2050
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 17, 2026, 8:21 AM EDT
Completed Not applicable Interventional

Healthy Eating Through Reduction Of Excess Sugar

NCT02948647
View directory record Official record
Conditions
NAFLD
Interventions
Standard of care plus sugar-reduction education
Other
Lead sponsor
University of Southern California
Other
Eligibility
12 Years to 18 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Oct 17, 2026, 8:21 AM EDT
Not listed No phase listed Observational

Hepatitis C (HCV) Cure and Kidney Health

NCT03407703
View directory record Official record
Conditions
Hepatitis C
Interventions
Elbasvir / Grazoprevir Oral Tablet [Zepatier]
Drug
Lead sponsor
San Francisco Veterans Affairs Medical Center
Federal
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2018 · Synced Oct 17, 2026, 8:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Interaction of Melatonin and MTNR1B Genotype on Glucose Control - Study 1

NCT02642640
View directory record Official record
Conditions
Glucose, Circadian Rhythm, Melatonin, Genes
Interventions
melatonin, placebo
Dietary Supplement · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years to 55 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 17, 2026, 8:21 AM EDT
Recruiting Not applicable Interventional

GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care

NCT05391126
View directory record Official record
Conditions
Colorectal Cancer, Pancreatic Cancer
Interventions
Irinotecan
Drug
Lead sponsor
Reema A. Patel
Other
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 17, 2026, 8:21 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

NCT05379985
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
Interventions
RMC-6236
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
754 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
21
States / cities
Orange, California • Santa Monica, California • Tampa, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 17, 2026, 8:21 AM EDT
Terminated Phase 4 Interventional Results available

Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study

NCT02717949
View directory record Official record
Conditions
Liver Disease
Interventions
sofosbuvir/ledipasvir, sofosbuvir, Ribavirin
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
3
States / cities
New York, New York • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Oct 17, 2026, 8:21 AM EDT
Completed Phase 1 Interventional

MANP in Hypertension and Metabolic Syndrome

NCT03781739
View directory record Official record
Conditions
Hypertension, Metabolic Syndrome
Interventions
MANP
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 13, 2020 · Synced Oct 17, 2026, 8:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Effect of Genotype on LY2216684

NCT01460381
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
LY2216684, Quinidine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2018 · Synced Oct 17, 2026, 8:21 AM EDT
Terminated Phase 3 Interventional Results available

Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP)

NCT00585312
View directory record Official record
Conditions
Adenomatous Polyposis Coli
Interventions
Celecoxib, Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
23
States / cities
Chicago, Illinois • Ann Arbor, Michigan • Omaha, Nebraska + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 17, 2026, 8:21 AM EDT
Terminated Phase 4 Interventional Results available

Pharmacogenomics of Anti-platelet Intervention-2 (PAPI-2) Study

NCT01452152
View directory record Official record
Conditions
Cardiovascular Diseases, Acute Coronary Syndrome
Interventions
clopidogrel, prasugrel
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
20 Years to 74 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
5
States / cities
Newark, Delaware • Baltimore, Maryland • Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Oct 17, 2026, 8:21 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders

NCT02120300
View directory record Official record
Conditions
Chronic HCV Infection
Interventions
LDV/SOF, SOF, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
13
States / cities
Sacramento, California • San Diego, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2016 · Synced Oct 17, 2026, 8:21 AM EDT